doi:10.1093/jac/dkz007engRequena, S.Lozano, AB.Caballero, E.García, F.Nieto, MC.Téllez, R.Fernández, JM.Trigo, M.Rodríguez-Avial, I.Martín-Carbonero, L.Miralles, P.Soriano, V.de, Mendoza, C.HIV-2 Spanish Study GroupRodríguez, C.Vera, M.Del, Romero, J.Marcaida, G.Ocete, MD.Caballero, E.Aguilera, A.BENITO, R.de, Lejarazu, RO.Rojo, S.Eirós, JM.Ramos, C.García, J.Paz, I.Trigo, M.Diz, J.García-Campello, M.Rodríguez-Iglesias, M.Hernández-Betancor, A.Martín, AM.Ramos, JM.Gimeno, A.Sánchez, V.Gómez-Hernando, C.Cilla, G.Pérez-Trallero, E.Fernández-Pereira, L.Niubó, J.Hernández, M.López-Lirola, AM.Gómez-Sirvent, JL.Force, L.Cabrera, J.Pérez, S.Morano, L.Raya, C.González-Praetorius, A.Cifuentes, C.Peñaranda, M.Nieto, MC.Montejo, JM.Roc, L.Viciana, I.Lozano, AB.Fernández-Fuertes, E.Fernández, JM.García-Bermejo, I.Gaspar, G.Téllez, R.Górgolas, M.Miralles, P.Pérez, L.Valeiro, M.Aldamiz, T.Margall, N.Suárez, A.Rodríguez-Avial, I.Requena, S.Benítez-Gutiérrez, L.Cuervas-Mons, V.de, Mendoza, C.Barreiro, P.Soriano, V.Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.ART-2019-111592Background: HIV-2 is a neglected virus despite estimates of 1–2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. Methods: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with inte- grase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modal- ities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. Results: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). Conclusions: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individ- uals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.2019http://zaguan.unizar.es/record/8767910.1093/jac/dkz007http://zaguan.unizar.es/record/87679oai:zaguan.unizar.es:87679info:eu-repo/grantAgreement/EC/FP7/223131/EU/Collaborative HIV and Anti-HIV Drug Resistance Network/CHAINThe Journal of antimicrobial chemotherapy 74, 5 (2019), 1357-1372All rights reservedhttp://www.europeana.eu/rights/rr-f/info:eu-repo/semantics/openAccess